LAB (Standard BioTools) Cyclically Adjusted Revenue per Share: $2.07 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LAB Standard BioTools Inc LAB
33 GF Score
Price $0.65
GF Value $0.71
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Standard BioTools Cyclically Adjusted Revenue per Share?

Standard BioTools LAB -3.77% 33 Cyclically Adjusted Revenue per Share is $2.07 as of Jun. 2026. GuruFocus rates LAB with a GF Score™ of 33/100 and a GF Value™ of $0.71 (Fairly Valued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Standard BioTools's adjusted revenue per share for the three months ended in Jun. 2026 was $0.051. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $2.07 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Standard BioTools's average Cyclically Adjusted Revenue Growth Rate was -18.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -11.50% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-08-20), Standard BioTools's current stock price is $0.64625. Standard BioTools's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was $2.07. Standard BioTools's Cyclically Adjusted PS Ratio of today is 0.31.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Standard BioTools was 2.73. The lowest was 0.28. And the median was 0.75.


Standard BioTools  (NAS:LAB) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Standard BioTools's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.64625/2.07
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Standard BioTools was 2.73. The lowest was 0.28. And the median was 0.75.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Standard BioTools Cyclically Adjusted Revenue per Share Related Terms


Standard BioTools Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Standard BioTools's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Standard BioTools Cyclically Adjusted Revenue per Share Chart

Standard BioTools Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.24 3.27 3.15 2.72 2.27

Standard BioTools Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.53 2.42 2.27 2.18 2.07

LAB vs CV, ELMD, CATX: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Standard BioTools's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Standard BioTools's Cyclically Adjusted PS Ratio falls into.


LAB
33GF Score
Standard BioTools Inc LAB
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Standard BioTools Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Standard BioTools's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.051/333.9520*333.9520
=0.051

Current CPI (Jun. 2026) = 333.9520.

Standard BioTools Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.763 241.428 1.055
201612 0.860 241.432 1.190
201703 0.873 243.801 1.196
201706 0.815 244.955 1.111
201709 0.717 246.819 0.970
201712 0.716 246.524 0.970
201803 0.650 249.554 0.870
201806 0.678 251.989 0.899
201809 0.738 252.439 0.976
201812 0.779 251.233 1.035
201903 0.516 254.202 0.678
201906 0.408 256.143 0.532
201909 0.381 256.759 0.496
201912 0.465 256.974 0.604
202003 0.392 258.115 0.507
202006 0.367 257.797 0.475
202009 0.550 260.280 0.706
202012 0.600 260.474 0.769
202103 0.439 264.877 0.553
202106 0.411 271.696 0.505
202109 0.374 274.310 0.455
202112 0.499 278.802 0.598
202203 0.344 287.504 0.400
202206 0.241 296.311 0.272
202209 0.325 296.808 0.366
202212 0.340 296.797 0.383
202303 0.318 301.836 0.352
202306 0.352 305.109 0.385
202309 0.320 307.789 0.347
202312 0.354 306.746 0.385
202403 0.155 312.332 0.166
202406 0.060 314.175 0.064
202409 0.059 315.301 0.062
202412 0.066 315.605 0.070
202503 0.053 319.799 0.055
202506 0.057 322.561 0.059
202509 0.051 324.800 0.052
202512 0.062 324.054 0.064
202603 0.054 330.213 0.055
202606 0.051 333.952 0.051

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $2.07 mean?
Standard BioTools (LAB) has a Cyclically Adjusted Revenue per Share of $2.07 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Standard BioTools and its competitors.
Is Standard BioTools' Cyclically Adjusted Revenue per Share too high?
Standard BioTools' current Cyclically Adjusted Revenue per Share is $2.07. Overall, Standard BioTools has a GF Score™ of 33/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Standard BioTools' Cyclically Adjusted Revenue per Share compare to CV and ELMD?
Standard BioTools' Cyclically Adjusted Revenue per Share of $2.07 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Standard BioTools and its competitors. Standard BioTools's current Cyclically Adjusted Revenue per Share is $2.07. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Standard BioTools stock overvalued right now?
Based on GuruFocus' analysis, Standard BioTools (LAB) is currently considered Fairly Valued. The stock's GF Value™ is $0.71, compared to a current price of $0.65 — trading 9% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $2.07. Standard BioTools' overall GF Score™ is 33/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Standard BioTools (LAB), the current Cyclically Adjusted Revenue per Share is $2.07 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Standard BioTools (LAB) Overvalued in 2026?

Based on GuruFocus' analysis, Standard BioTools stock appears to be undervalued. The current stock price of $0.65 is trading 9% below its estimated GF Value™ of $0.71. GuruFocus considers Standard BioTools to be Fairly Valued.

Key valuation signals for LAB:

  • Cyclically Adjusted Revenue per Share: $2.07
  • GF Value™: $0.71 vs. price of $0.65 (9% below fair value)
  • GF Score™: 33/100 with 5 warning signs

No single metric tells the full story. See the LAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Standard BioTools Business Description

Other Exchanges FLB:Germany
Address 50 Milk Street, 10th Floor, Boston, MA, USA, 02109
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. The company operates in one segment. Its technology includes: Genomics; Single-cell proteomics; Spatial proteomics. Its platforms include: Biomark X9 System, CyTOF XT system, and Hyperion XTi Imaging System. The company offers a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. Geographically, it operates in Americas; EMEA and Asia-Pacific.
33GF Score

Get the complete analysis for LAB

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.65
Price
$0.71
GF Value